Indegene Ltd Share Price

Q: What is the share price of Indegene Ltd today?

Indegene Ltd share price as on 22 Jan 2025 is ₹658.7

Miscellaneous - Medium / Small

NSE: INDGN Small Cap ISIN: INE065X01017

As on 22 January 2025 at 15:53 IST

₹658.70

-0.60

(-0.09%)

Sell Buy

About Indegene Ltd

Indegene Ltd. is a digital-first life sciences commercialization company that provides a range of services to biopharmaceutical and medical device companies. It operates in the healthcare and technology sectors. Indegene has been a significant player since its inception in 1998. With decades of experience, the company has established itself as a trusted partner for some of the largest global biopharmaceutical companies. The headquarters of Indegene is located in Bangalore, Karnataka, India. Indegene’s main products and services include enterprise commercial solutions, medical transformation, data and analytics, product development, and omnichannel activation. Read More...

Over 1 Month

11.97%

Over 6 Months

15.87%

Over 1 Year

15.48%

Over 3 Years

Indegene Ltd Summary

Close ₹ 658.70

Open ₹ 655.50

High ₹ 666.05

Low ₹ 652.90

Volume 7,68,633

Net Turnover (in ₹) ₹ 30,20,43,460.45

52Wk High ₹ 736.30

52Wk Low ₹ 470.10

52Wk High / Low

470.10

736.30

Indegene Ltd Fundamentals

Key Financial Data

Market Cap (in ₹Cr) ₹ 15,775

EPS (TTM) 6.52

Book Value (BV) 74.12

Div. Yield -

P/E (TTM) 101.12

Price/Book Value 8.90

Delivery % 44.72 %

Face Value 2

Key Ratios

PE Ratio -

PB Ratio -

EV to Sales -

PEG Ratio -

ROA 13.32

ROE 15.77

Debt-Equity 0.05

Net Profit Margin 13.19

Operating Profit Margin 20.88

Indegene Ltd Financials

Profit and Loss

Consolidated

Standalone

Yearly

Quarterly

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Total Revenue	2,665.90	2,364.10	1,690.50	996.92	646.38
Total Expenses	2,209.70	2,001.10	1,417.10	768.25	527.45
Profit Before Tax	458.60	363	226.50	231.46	75.80
Profit After Tax	336.70	266.10	162.82	185.68	49.68
Operating Profit after Depreciation	505.60	394.30	279.36	235.63	127.77

Balance Sheet

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Fixed Assets	645.80	664.10	137.72	85.92	119.26
Total Non Current Assets	754.80	755.20	223.44	136.75	182.68
Total Current Assets	1,790.80	1,448.70	1,130.03	459.29	417.57
TOTAL ASSETS	2,545.60	2,203.90	1,353.47	596.04	600.25
Total Shareholder's Fund	1,429.10	1,063.80	763.90	324.51	-104.68

Cash Flow

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Cash from Operating Activities	507.70	130.20	297.04	172.03	22.27
Net Cash used in Investing Activities	-326.50	-896	-157.60	-81.03	-15.78
Net Cash used in Financing Activities	-66.20	333.10	233.48	-131.51	136.36

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Total Revenue	1,095.90	1,042.50	864.50	535.10	349.70
Total Expenses	915.30	865.90	694.60	381.70	265.40
Profit Before Tax	180.60	176.60	169.90	156.40	40.60
Profit After Tax	137.90	130.20	132.70	129.50	26.80
Operating Profit after Depreciation	187.20	183	172.90	156.90	87.70

Balance Sheet

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Fixed Assets	56.10	78.30	72	40.60	31.30
Total Non Current Assets	469.30	334.80	315.60	154.70	312.60
Total Current Assets	751	702.90	534.50	217.90	118.50
TOTAL ASSETS	1,220.30	1,037.70	850.10	372.60	431.10
Total Shareholder's Fund	953.80	795.30	650	253.90	-3.10

Cash Flow

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Cash from Operating Activities	176.20	81.90	38.20	53.30	89.60
Net Cash used in Investing Activities	-189	-51	-266.90	-34.10	-51.10
Net Cash used in Financing Activities	-15.80	-16.90	244.90	-37.10	-18.50

Particulars (in ₹ Cr.)	2024-09	2024-06	2024-03	2023-12	2023-09
Total Revenue	686.80	676.50	673	673.40	635.70
Total Expenses	560.70	547.60	534.30	524.50	514.60
Profit Before Tax	124.10	119.60	133.50	132.30	100.60
Profit After Tax	91.70	87.70	94.80	98.80	75
Operating Profit after Depreciation	147.50	151.40	161.90	162	132.70

Particulars (in ₹ Cr.)	2024-09	2024-06	2024-03	2023-12	2023-09
Total Revenue	281.70	258.60	272.50	260	260.50
Total Expenses	235.30	219.10	226.10	223	217.10
Profit Before Tax	61	45.10	60.40	40.80	39.40
Profit After Tax	44.80	32.60	48.90	29.60	29.30
Operating Profit after Depreciation	68.80	53.20	69.50	49	49.40

Indegene Ltd Technicals

Support and Resistance

S3 S2 S1 Pivot R1 R2 R3

S1 649.63

S2 639.97

S3 623.93

Pivot 665.67

R1 675.33

R2 691.37

R3 701.03

Moving Average

20 SMA 619.67

50 SMA 627.38

100 SMA 645.75

200 SMA -

Indegene Ltd Corporate Actions

Dividend

Bonus

Splits

Rights

AGM

EGM

No available data

Indegene Ltd Peer Comparison

Company	Price	Market Cap (in ₹ Cr)
Indegene Ltd	₹659.30	₹15,775
Max Healthcare Institute Ltd	₹1,078.10	₹1,04,805.56
Apollo Hospitals Enterprise Ltd	₹6,918.65	₹99,479.57
Fortis Healthcare Ltd	₹639.80	₹48,302.22
Syngene International Ltd	₹832.10	₹33,495.10
Global Health Ltd	₹1,055.75	₹28,356.11

Indegene Ltd News

Indegene inks pact with CliniOps to accelerate clinical trials

Indegene announced a strategic partnership with CliniOps, a leading provider of advanced digital clinical trial solutions to drive innovative digital transformation in clinical trial processes and achieve better patient outcomes.

10 Jan 2025, 11:34 am

CliniOps Inc. announces strategic partnership with Indegene

10 Jan 2025, 10:15 am

Indegene wins Deloitte Technology Fast 50 India 2024 Award

09 Dec 2024, 08:56 am

Indegene opens new center in Hyderabad

18 Nov 2024, 02:08 pm

Indegene schedules board meeting

On 28 October 2024

23 Oct 2024, 10:20 am

Indegene Ltd Stock Analysis

Annual revenue for Indegene Ltd increased by 5.12% to ₹1,095.90 crore in FY 2024 from ₹1,042.50 crore in FY 2023.
Annual Net Profit for Indegene Ltd increased by 5.91% to ₹137.90 crore in FY 2024 from ₹130.20 crore in FY 2023.
Promoter Shareholding in Indegene Ltd remains unchanged by 0.00% in the most recent quarter, from 0% in September 2024 to 0% in December 2024.
Indegene Ltd delivered a 1-year return of 15.48% compared to the Nifty 50, which provided a return of 8.41% as of the last trading session.
Indegene Ltd share price moved down by 0.09% from its previous close of INR ₹659.30. The latest Indegene Ltd share price is INR ₹658.70.
Indegene Ltd share price today has been at a low of 652.90 and a high of 666.05. Over the past 52 weeks, the Indegene Ltd share price has seen a low of 470.10 and a high of 736.30.

About Indegene Ltd

Indegene Ltd. is a digital-first life sciences commercialization company. It provides a range of services to biopharmaceutical and medical device companies. The company helps these enterprises develop products and bring them to market. It also helps them in growing their impact throughout the product life cycle. Indegene combines healthcare expertise with tailored technology and an agile operating model. This allows them to deliver personalized, omnichannel experiences for patients and healthcare professionals.

Indegene has been a key player in the healthcare and technology sectors since its founding in 1998. With decades of experience, the company has built a strong reputation. It is now a trusted partner for some of the largest global biopharmaceutical companies. Indegene's headquarters is located in Bangalore, Karnataka. It serves as the central hub for the company's operations and strategic initiatives.

The company does not have a promoter shareholding. However, it has a public shareholding of 92.01% in the company. It also has a team of professional managerial promoters who manage the operations of the company. They are as follows-

Manish Gupta
Sanjay Suresh Parikh
Rajesh Bhaskaran Nair
Krishnamurthy Venugopala Tenneti
Ashish Gupta

Indegene’s main products and services include enterprise commercial solutions, medical transformation, data and analytics, and product development. It also offers omni channel activation. These offerings are designed to improve the effectiveness and efficiency of healthcare operations. They help clients achieve better outcomes and enhance patient care.

Indegene may not be the largest in terms of market share or market capitalization. However, it is highly regarded for its innovative solutions and customer-centric approach. The company’s stock is well-regarded in the market, reflecting its strong performance and market presence.

The registered office of Indegene Ltd. is in Bengaluru, Karnataka and the office of the registrar is in Mumbai, Maharashtra. Indegene Ltd. stands out as a major player in the healthcare and technology sectors. It has a rich history, a robust product portfolio, and a strong market presence. Its strategic partnerships and efficient management continue to drive the company forward. This propels Indegene towards sustained growth and industry leadership.

The Impact of Indegene Limited

Indegene Ltd. has made a significant impact on the life sciences and healthcare sectors. This is due to its innovative digital solutions and services. Established in 1998, the company has grown significantly. It has become a trusted partner for biopharmaceutical and medical device companies. Indegene’s contributions span product development and lifecycle management. These efforts help its clients achieve better outcomes and improve patient care.

One of Indegene's primary impacts is its role in transforming the commercialization process. This is particularly significant for life sciences companies. The company provides a range of services, including consulting and enterprise medical solutions. These services help clients navigate the complex landscape of product development and market entry.

Indegene’s focus on digital innovation has been a game-changer for the industry. The company leverages advanced technologies like machine learning and data analytics. These technologies enhance its service offerings. They are designed to meet the unique needs of each client.

The company’s impact extends to improving patient engagement and outcomes. Indegene’s omnichannel activation services ensure healthcare professionals receive timely and relevant information. This includes updates about new treatments and therapies. This approach enhances patient adherence to prescribed treatments and improves overall health outcomes. Additionally, Indegene’s digital platforms improve communication between patients and healthcare providers. This leads to more informed and empowered patients.

Indegene has also played a crucial role in supporting clinical trials and research. The company’s enterprise clinical solutions streamline the clinical trial process. This includes everything from patient recruitment to data management. These solutions help reduce the time and cost of bringing new therapies to market. As a result, they accelerate the availability of innovative treatments for patients.

The company’s commitment to sustainability and social responsibility further amplifies its impact. Indegene engages in various corporate social responsibility initiatives aimed at improving access to quality education and healthcare. These initiatives include partnerships with leading educational and healthcare organizations. They aim to support the missions of these organizations. Indegene’s CSR efforts reflect its dedication to making a positive difference in the communities it serves.

Indegene’s strategic collaborations and partnerships have also contributed to its impact. The company works with a range of stakeholders, including pharmaceutical companies and technology firms. These partnerships help deliver integrated solutions. These collaborations allow Indegene to leverage additional resources and expertise. This enhances its ability to tackle complex challenges in the life sciences sector.

The company’s financial performance and growth trajectory are indicative of its impact on the industry. Indegene has consistently achieved strong revenue growth, driven by its innovative solutions and customer-centric approach. The company’s ability to attract significant investments, such as the $200 million from Carlyle and Brighton Park. This highlights its potential for continued growth and its prospects for success.

Indegene’s impact is also evident in its role as a thought leader in the industry. The company regularly publishes research and insights on emerging trends and best practices in life sciences commercialization. These publications provide valuable guidance to industry stakeholders. They help them navigate the evolving landscape and make informed decisions.